|Application ||WB, IHC-P, E|
|Other Accession||NP_059979.2, NP_612631.1|
|Calculated MW||28087 Da|
|Antigen Region||78-106 aa|
|Other Names||Kallikrein-15, 3421-, ACO protease, KLK15|
|Target/Specificity||This KLK15 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 78-106 amino acids from the Central region of human KLK15.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||KLK15 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Protease whose physiological substrate is not yet known.|
|Tissue Location||Highest expression in the thyroid gland. Also expressed in the prostate, salivary, and adrenal glands and in the colon testis and kidney.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. In prostate cancer, this gene has increased expression, which indicates its possible use as a diagnostic or prognostic marker for prostate cancer. The gene contains multiple polyadenylation sites and alternative splicing results in multiple transcript variants encoding distinct isoforms.
Rabien, A., et al. Int. J. Cancer 127(10):2386-2394(2010)
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
Han, S., et al. Hum. Immunol. 71(7):727-730(2010)
Gallagher, D.J., et al. Clin. Cancer Res. 16(10):2819-2832(2010)
Klein, R.J., et al. Cancer Prev Res (Phila) 3(5):611-619(2010)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.